<i>In vitro</i> activity of a novel antifungal compound, MYC-053, against clinically significant antifungal-resistant strains of <i>Candida glabrata, Candida auris, Cryptococcus neoformans</i> , and <i>Pneumocystis</i> spp

George Tetz(Human BioMolecular Research Institute), Victor Tetz(First Pavlov State Medical University of St. Petersburg), Daria Vikina, Margaret S. Collins(University of Cincinnati Medical Center)
bioRxiv (Cold Spring Harbor Laboratory)
September 6, 2018
Cited by 1


Related Papers